Host determinants of alphavirus replication

甲病毒复制的宿主决定因素

基本信息

  • 批准号:
    8260350
  • 负责人:
  • 金额:
    $ 36.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-05-15 至 2015-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Alphaviruses are pathogens of humans and livestock with worldwide distribution. The classification of some species as select agents in conjunction with their impact on public health makes understanding their interaction with the host and development of interventions a high priority. Alphaviruses are obligatorily transmitted by a hematophagous arthropod vector in which a lifelong persistent infection is established. This pattern of infection implies an effective but incomplete immune response that preserves host fitness while allowing virus replication to continue thus facilitating virus transmission. A major impediment to understanding the critical virus-host interactions has been the inability to genetically manipulate the host organism. Drosophila melanogaster represents an excellent experimental system for elucidating the genetic, molecular, and biochemical mechanisms underlying numerous physiological and developmental processes. The proposed research aims to exploit the power of Drosophila genetics to define the recently characterized interactions between alphaviruses and two arthropod innate immune response pathways. A system for the analysis of alphavirus replication has been established in which an alphavirus replicon sequence encoding a reporter gene is expressed from the genome of Drosophila under the control of the GAL4-UAS misexpression system. The resulting replication of the viral RNA is observable through reporter gene activity. Mutational analyses of host pathways using this alphavirus replicon fly line have demonstrated an antiviral role for the Imd- and JAK-STAT pathways. This system has been further developed to produce infectious particles. Co-expression in Drosophila of the replicon and viral structural proteins leads to the production of replicon containing particles capable of a single round of infection. These basic tools will be used in combination with Drosophila genetics to (i) determine the viral components responsible for activation of Imd- and JAK-STAT pathways; (ii) identify host genes involved in virus-induced innate immune response; (iii) characterize host requirements for virus spread. The proposed research combines the power of Drosophila genetics with comparative genomics and molecular virology in order to advance our understanding of the interaction between alphaviruses and an arthropod host. PUBLIC HEALTH RELEVANCE: Understanding virus-host interactions is essential to understanding the outcome of infection and determining means of interrupting transmission. The proposed research aims to examine the host response to alphaviruses using a model genetic system.
描述(由申请人提供):甲病毒是人类和牲畜的病原体,在世界范围内分布。将某些物种分类为选定的媒介,并结合它们对公共健康的影响,使了解它们与宿主的相互作用和制定干预措施成为当务之急。甲病毒必须通过食血节肢动物载体传播,并在其中建立终生持续感染。这种感染模式意味着有效但不完整的免疫反应,可以保持宿主健康,同时允许病毒继续复制,从而促进病毒传播。了解关键的病毒与宿主相互作用的一个主要障碍是无法对宿主生物体进行基因操纵。黑腹果蝇代表了一个出色的实验系统,用于阐明众多生理和发育过程背后的遗传、分子和生化机制。拟议的研究旨在利用果蝇遗传学的力量来定义最近表征的甲病毒和两种节肢动物先天免疫反应途径之间的相互作用。已经建立了用于分析甲病毒复制的系统,其中编码报告基因的甲病毒复制子序列在GAL4-UAS错误表达系统的控制下从果蝇基因组表达。由此产生的病毒 RNA 复制可通过报告基因活性观察到。使用该甲病毒复制子飞系对宿主途径进行的突变分析已证明 Imd- 和 JAK-STAT 途径具有抗病毒作用。该系统已进一步开发用于生产传染性颗粒。复制子和病毒结构蛋白在果蝇中的共表达导致产生能够进行单轮感染的含有复制子的颗粒。这些基本工具将与果蝇遗传学结合使用,以 (i) 确定负责 Imd- 和 JAK-STAT 途径激活的病毒成分; (ii) 鉴定参与病毒诱导的先天免疫反应的宿主基因; (iii) 描述病毒传播的宿主要求。拟议的研究将果蝇遗传学与比较基因组学和分子病毒学的力量结合起来,以增进我们对甲病毒与节肢动物宿主之间相互作用的理解。 公共卫生相关性:了解病毒与宿主的相互作用对于了解感染的结果和确定中断传播的方法至关重要。拟议的研究旨在使用模型遗传系统检查宿主对甲病毒的反应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD W HARDY其他文献

RICHARD W HARDY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD W HARDY', 18)}}的其他基金

Epitranscriptomic Regulation of Alphavirus Replication and Transmission
甲病毒复制和传播的表观转录调控
  • 批准号:
    10177869
  • 财政年份:
    2020
  • 资助金额:
    $ 36.49万
  • 项目类别:
Epitranscriptomic Regulation of Alphavirus Replication and Transmission
甲病毒复制和传播的表观转录调控
  • 批准号:
    10040109
  • 财政年份:
    2020
  • 资助金额:
    $ 36.49万
  • 项目类别:
Host determinants of alphavirus replication
甲病毒复制的宿主决定因素
  • 批准号:
    8651866
  • 财政年份:
    2010
  • 资助金额:
    $ 36.49万
  • 项目类别:
Host determinants of alphavirus replication
甲病毒复制的宿主决定因素
  • 批准号:
    8458620
  • 财政年份:
    2010
  • 资助金额:
    $ 36.49万
  • 项目类别:
Host determinants of alphavirus replication
甲病毒复制的宿主决定因素
  • 批准号:
    7948358
  • 财政年份:
    2010
  • 资助金额:
    $ 36.49万
  • 项目类别:
Host determinants of alphavirus replication
甲病毒复制的宿主决定因素
  • 批准号:
    8070476
  • 财政年份:
    2010
  • 资助金额:
    $ 36.49万
  • 项目类别:
AN ORGANISMAL APPROACH TO VIRAL HOST FACTOR DISCOVERY
发现病毒宿主因子的有机方法
  • 批准号:
    7456260
  • 财政年份:
    2008
  • 资助金额:
    $ 36.49万
  • 项目类别:
AN ORGANISMAL APPROACH TO VIRAL HOST FACTOR DISCOVERY
发现病毒宿主因子的有机方法
  • 批准号:
    7563272
  • 财政年份:
    2008
  • 资助金额:
    $ 36.49万
  • 项目类别:
MECHANISTIC STUDIES ON SINDBIS VIRUS RNA REPLICATION
Sinbis病毒RNA复制机制研究
  • 批准号:
    6518848
  • 财政年份:
    2000
  • 资助金额:
    $ 36.49万
  • 项目类别:
MECHANISTIC STUDIES ON SINDBIS VIRUS RNA REPLICATION
Sinbis病毒RNA复制机制研究
  • 批准号:
    6385153
  • 财政年份:
    2000
  • 资助金额:
    $ 36.49万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 36.49万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 36.49万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 36.49万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 36.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 36.49万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 36.49万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 36.49万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 36.49万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 36.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 36.49万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了